- Home
- PHUN vs AVTX Comparison
PHUN vs AVTX Comparison
Compare PHUN & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHUN | AVTX |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.3M | 956.7M |
| IPO Year | 2016 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PHUN | AVTX |
|---|---|---|
| Price | $2.06 | $18.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $7.25 | ★ $40.57 |
| AVG Volume (30 Days) | 110.5K | ★ 1.9M |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 39.36 | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,883,000.00 | $27,813,137.00 |
| Revenue This Year | $89.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 15.57 | ★ 2312.27 |
| 52 Week Low | $1.56 | $4.73 |
| 52 Week High | $3.70 | $24.27 |
Technical Indicators
Market Signals| Indicator | PHUN | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.87 | 61.89 |
| Support Level | $1.79 | $13.13 |
| Resistance Level | $2.10 | $19.06 |
| Average True Range (ATR) | 0.06 | 1.32 |
| MACD | 0.02 | 0.37 |
| Stochastic Oscillator | 67.01 | 79.48 |
Price Performance
Historical ComparisonAbout PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services. Development services for customers who wish to have a customized application experience; and In-app advertising services for mobile audience building, user acquisition, application discovery, audience engagement and monetization.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.